CoChat

Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?

Open access
Thebault, Eric, Piperno-Neumann, Sophie, Tran, Diep, Pacquement, Hélène, Marec-Berard, Perrine, Lervat, Cyril, Castex, Marie-Pierre, Cleirec, Morgane, Bompas, Emmanuelle, Vannier, Jean-Pierre, Plantaz, Dominique, Saumet, Laure, Verite, Cecile, Collard, Olivier, Pluchart, Claire, Briandet, Claire, Monard, Laure, Brugieres, Laurence, Le Deley, Marie-Cécile, Gaspar, Nathalie · 2021 · Cancers
Cited by 22

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The purpose was to describe first and subsequent relapses in patients from the OS2006/Sarcome-09 trial, to help future trial design. We prospectively collected and analysed relapse data of all French patients included in the OS2006/Sarcome-09 trial, who had achieved a first complete remission. 157 patients experienced a first relapse. The median interval from diagnosis to relapse was 1.7 year (range 0.5–7.6). The first relapse was metastatic in 83% of patients, and disease was not measurable according to RECIST 1.1 criteria in 23%. Treatment consisted in systemic therapy (74%) and surgical resection (68%). A quarter of the patients were accrued in a phase-II clinical trial. A second complete remission was obtained for 79 patients. Most of them had undergone surgery (76/79). The 3-year progression-free and overall survival rates were 21% and 37%, respectively. In patients who achieved CR2, the 3y-PFS and OS rates were 39% and 62% respectively. Individual correlation between subsequent PFS durations was poor. For osteosarcoma relapses, we recommend randomised phase-II trials, open to patients from all age categories (children, adolescents, adults), not limited to patients with measurable disease (but stratified according to disease status), with PFS as primary endpoint, response rate and surgical CR as secondary endpoints.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13071683

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 22

Metadata

Authors
Thebault, E., Piperno-Neumann, S., Tran, D., Pacquement, H., Marec-Berard, P., Lervat, C., Castex, M.-P., Cleirec, M., Bompas, E., Vannier, J.-P., Plantaz, D., Saumet, L., Verite, C., Collard, O., Pluchart, C., Briandet, C., Monard, L., Brugieres, L., Le Deley, M.-C., & Gaspar, N.
Venue
Cancers
Publisher
MDPI AG
Published
2021-04-02
Volume
13
Issue
7
Pages
1683
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3143999709
Cited by
22
References
12
FWCI
1.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.